Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis

Yonsei University

Status and phase

Unknown

Phase 2

Conditions

Rectal Cancer, Metastatic

Treatments

Drug: chemotherapy

Radiation: radiotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT03022734

4-2016-0410

Details and patient eligibility

About

The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy. Radiation therapy is followed by additional chemotherapy to prevent the progression of systemic metastasis, and to reduce the incidence of rectal carcinoma including metastasis.

Enrollment

40 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

pathologically confirmed for unresectable (impossible to try Total mesorectal excision) rectal cancer with liver metastasis
over 19 years
Eastern Cooperative Oncology Group 0-1
Proper organ function
more than one target lesion (standard by Response Evaluation Criteria in Solid Tumors 1.1)
Who should sign on the Informed consent form before participate the trial.

Exclusion criteria

Metastasis in other organ except liver
Chronic active hepatitis or cirrhosis
History of treatment for metastatic colorectal cancer
Subject pregnant or breast feeding
Uncontrolled disease
Have had adjuvant therapy
Uncontrolled peripheral nerve infection
Alcoholic or drug addict
Subject currently is enrolled in or ≤30 days from ending other clinical trial.
History of other type of cancer except resolved from skin cancer and cervical cancer.